Item 2.02 Results of Operations and Financial Condition.

On January 10, 2023, Kymera Therapeutics, Inc. (the "Company") issued a press release announcing its preliminary cash balance as of December 31, 2022, a business update and further details on its 2023 key objectives and outlook (the "Press Release"). A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Although it has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2022, the Company announced on January 10, 2023, that it expects to report that it had approximately $560 million of cash, cash equivalents and investments as of December 31, 2022.

The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is unaudited and preliminary and does not present all information necessary for an understanding of the Company's financial condition as of December 31, 2022 and its results of operations for the three months and year ended December 31, 2022. The audit of the Company's consolidated financial statements for the year ended December 31, 2022 is ongoing and could result in changes to the information set forth above.

The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.



Item 9.01. Exhibits


(d) Exhibits

Exhibit
  No.       Description

99.1          Press Release issued by Kymera Therapeutics, Inc. dated January 10,
            2023, furnished herewith.

104         Cover Page Interactive Data (embedded within the Inline XBRL
            document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses